SHR-1811 plus carboplatin for advanced HER2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have advanced breast cancer that has spread or cannot be removed, with some level of HER2 protein (from low to high).
- You have already tried standard treatments for advanced cancer and they stopped working.
- You have not received certain newer antibody-drug conjugate treatments (like T-DXd) or any such drug if your HER2 is low or ultra-low.
- Your daily activity level is good (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after 4 cycles of standard pre-surgery treatment. The goal is to see if this drug can help improve outcomes before surgery.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
This trial combines two targeted medications (SHR-A1811 and pyrotinib) for people with HER2-positive breast cancer that has spread or cannot be removed with surgery. It is for those whose cancer has stopped responding to previous HER2-targeted therapies or chemotherapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.